Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy

Gabriela Rozic, PhD, Paukov Lena, MSc, Jana Jakubikova, PhD, Duek Adrian, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Merav Leiba, MD

Blood (2015) 126 (23): 5348.

https://doi.org/10.1182/blood.V126.23.5348.5348

Published: 2015

Journal Articles

Therapeutic Efficacy of Semisynthetic Supra Perfusion Resuscitation Fluids, EAF Peg Alb and EAF Peg Hb, Are Differentiated By Their Cerebral Effects in Animal Models of Sickle Cell Disease

Craig A Branch, MS, PhD, Min-Hui Cui, PhD, Sangeetha Thangaswamy, PhD, Nicholas Branch, Seetharama Acharya

Blood (2015) 126 (23): 773.

https://doi.org/10.1182/blood.V126.23.773.773

Published: 2015

Journal Articles

The Prognostic Advantage of Calreticulin Mutations in Myelofibrosis Might be Confined to Type 1 or “type 1-like” Calreticulin Variants

Ayalew Tefferi, MD, Terra L Lasho, PhD, Alexander Tischer, PhD, Emnet A Wassie, MD, Christy Finke, BS, Alem A Belachew, Rhett Ketterling, MD, Curtis A Hanson, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 3166.

https://doi.org/10.1182/blood.V124.21.3166.3166

Published: 2014

Journal Articles

Oral Gene Delivery of Factor IX Muteins Formulated As Chitosan Nanoparticles for the Treatment of Hemophilia B

Patricia Quade-Lyssy, Christopher Ungerer, Peter Milanov, PhD, Erhard Seifried, MD, PhD, Jörg Schüttrumpf, MD

Blood (2012) 120 (21): 2048.

https://doi.org/10.1182/blood.V120.21.2048.2048

Published: 2012

Journal Articles

Expression Profile Signature to Predict Response to Bortezomib and Dexamethasone Combination Therapy in Newly-Diagnosed Myeloma: Moving towards Prospective Prediction

Nikhil C. Munshi, MD, Cheng Li, Stephane Minvielle, Samir B Amin, Philippe Moreau, Florence Magrangeas, Kenneth C Anderson, MD, Herve Avet-Loiseau

Blood (2008) 112 (11): 2746.

https://doi.org/10.1182/blood.V112.11.2746.2746

Published: 2008

Journal Articles

Procoagulant Assessment of Topical Battlefield Hemostats Using a Novel Semi-Automated Whole Blood Clotting Assay System.

Keith A. Moskowitz, PhD

Blood (2007) 110 (11): 3161.

https://doi.org/10.1182/blood.V110.11.3161.3161

Published: 2007

NARROW

STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy

Therapeutic Efficacy of Semisynthetic Supra Perfusion Resuscitation Fluids, EAF Peg Alb and EAF Peg Hb, Are Differentiated By Their Cerebral Effects in Animal Models of Sickle Cell Disease

The Prognostic Advantage of Calreticulin Mutations in Myelofibrosis Might be Confined to Type 1 or “type 1-like” Calreticulin Variants

Oral Gene Delivery of Factor IX Muteins Formulated As Chitosan Nanoparticles for the Treatment of Hemophilia B

Expression Profile Signature to Predict Response to Bortezomib and Dexamethasone Combination Therapy in Newly-Diagnosed Myeloma: Moving towards Prospective Prediction

Procoagulant Assessment of Topical Battlefield Hemostats Using a Novel Semi-Automated Whole Blood Clotting Assay System.

Email alerts

ASH Publications

American Society of Hematology

STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy

Therapeutic Efficacy of Semisynthetic Supra Perfusion Resuscitation Fluids, EAF Peg Alb and EAF Peg Hb, Are Differentiated By Their Cerebral Effects in Animal Models of Sickle Cell Disease

The Prognostic Advantage of Calreticulin Mutations in Myelofibrosis Might be Confined to Type 1 or “type 1-like” Calreticulin Variants

Oral Gene Delivery of Factor IX Muteins Formulated As Chitosan Nanoparticles for the Treatment of Hemophilia B

Expression Profile Signature to Predict Response to Bortezomib and Dexamethasone Combination Therapy in Newly-Diagnosed Myeloma: Moving towards Prospective Prediction

Procoagulant Assessment of Topical Battlefield Hemostats Using a Novel Semi-Automated Whole Blood Clotting Assay System.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only